摘要
目的分析采用奥沙利铂联合卡培他滨的方案治疗中晚期大肠癌的临床疗效以及安全性。方法选取启东市人民医院及启东市中医院2013年1月—2017年12月所收治的中晚期大肠癌患者38例,采用数字随机表法分为研究组和参照组,每组各19例,研究组患者给予奥沙利铂联合卡培他滨,参照组患者给予奥沙利铂联合氟尿嘧啶,对比2组患者治疗效果以及不良反应发生情况。结果研究组患者治疗总有效率78.95%,参照组患者治疗总有效率73.68%,对比差异无统计学意义(χ~2=0.145 6,P>0.05)。研究组与参照组患者不良反应情况,选取患者不同症状当中最多的例数进行分析对比,研究组无不良反应12例,参照组无不良反应8例,研究组轻度不良反应8例,参照组轻度不良反应6例,研究组中度不良反应5例,参照组中度不良反应7例,研究组重度不良反应2例,参照组重度不良反应6例。结论采用奥沙利铂联合卡培他滨方案对比奥沙利铂联合氟尿嘧啶方案治疗中晚期大肠癌治疗效果无显著差异,但奥沙利铂联合卡培他滨对患者造成的不良反应较少,临床安全性也相对较高,可在临床当中广泛推广运用。
Objective To analyze the clinical efficacy and safety of oxaliplatin combined with capecitabine in the treatment of advanced colorectal cancer. Methods A total of 38 patients with advanced colorectal cancer admitted to Qidong People＇s Hospital and Qidong Traditional Chinese Medicine Hospital from January 2013 to December 2017 were enrolled. The patients were divided into study group and reference group by numerical random table method, with 19 cases in each group. Patients in the study group were given oxaliplatin plus capecitabine, and patients in the reference group were given oxaliplatin plus fluorouracil. The therapeutic effects and adverse reactions of the two groups were compared. Results The total effective rate of the study group was 78.95%. The total effective rate of the reference group was 73.68%. The data comparison χ2 value was 0.1456, and the p value was 0.7027. There was no significant difference between the groups （P〉0.05）. The adverse reactions of the study group and the reference group were analyzed. The highest number of patients with different symptoms were analyzed.（There were no adverse reactions in the study group, 12 cases in the reference group, 8 cases in the reference group, and 8 cases in the study group. There were 6 cases of mild adverse reactions, 5 cases of moderate adverse reactions in the study group, 7 cases of moderate adverse reactions in the reference group, 2 cases of severe adverse reactions in the study group, and 6 cases of severe adverse reactions in the reference group. Conclusion There is no significant difference in the efficacy of oxaliplatin combined with capecitabine in the treatment of advanced colorectal cancer compared with oxaliplatin combined with fluorouracil. However, oxaliplatin combined with capecitabine has fewer adverse reactions to patients. The clinical safety is relatively high, which can be widely used in clinical practice.
作者
周芦忠
ZHOU Lu-zhong(Department of Oncology,Qidong Hospital of Traditional Chinese Medicine,Qidong,Jiangsu Province,226200 China)
出处
《系统医学》
2018年第19期134-136,共3页
Systems Medicine
关键词
治疗效果
联合治疗
安全性
奥沙利铂
中晚期
大肠癌
卡培他滨
Therapeutic effect
Combination therapy
Safety
Oxaliplatin
Middle and late stage
Colorectal cancer
Capecitabine
